The AHA today responded to a RAND Corporation study that found certain prices paid to hospitals by private health plans are high relative to Medicare. The study examined hospital prices for a limited number of employers and health plans from 2016 to 2018.
 
“It is unfortunate that RAND continues to make broad claims about pricing based on a cherry-picked and limited data set,” said AHA Executive Vice President Tom Nickels. “For example, the study again perpetuates erroneous suggestions that Medicare payments should be used as a benchmark for private insurers, in spite of Medicare reimbursing well below the cost of providing care. The authors also rely on research short-cuts. This includes a hand-picked sample of employers and insurers whose claims represent just 0.7% of inpatient admissions and 1.8% of outpatients visits over the study period, as well as measuring quality through Leapfrog data that may be old or imprecise. These concerns are compounded by a global pandemic that represents the greatest financial threat in history for hospitals and health systems. The case for pulling resources from care providers was weak from the start. It is beyond reckless to advance this approach now.”

Related News Articles

Headline
For future public health emergencies, the Centers for Medicare & Medicaid Services should improve how it sets Medicare rates for clinical diagnostic…
Headline
The Centers for Medicare & Medicaid Services April 4 finalized changes to the Medicare Advantage and prescription drug programs for contract year 2025…
Headline
The Centers for Medicare & Medicaid Services April 1 finalized proposed changes to Medicare Advantage plan capitation rates and Part C and Part D…
Headline
The AHA March 29 released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and regulation of…
Headline
CMS March 28 released an updated online validator tool that hospitals can use to test price transparency machine-readable files against the new format and data…
Headline
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 41 Part B prescription drugs from 20% to somewhere…